Clavis Pharma
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Clavis Pharma sits in the upper quartile of US sponsors by registered trial count (#2,411 of 15,742 sponsors by registered trial count).
Clavis Pharma: 5 sponsored US clinical trials, none currently recruiting.
Clavis Pharma sponsors 5 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 5 completed. 1 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Acute Myeloid Leukemia (AML), with 1 trials.
Upper-quartile sponsor footprint
Clavis Pharma sits in the upper quartile of the sponsor corpus (#2,411 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
5 total, page 1 of 1
Study of Elacytarabine Versus Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia (AML)
NCT01147939
A Study of Elacytarabine (CP-4055) Plus Idarubicin as Second Course Remission-Induction Therapy in Patients With Acute Myeloid Leukaemia
NCT01035502
Multicentre, Dose Finding, Ph II,CP-4055 in Comb. With Sorafenib - Patients With Metastatic Malignant Melanoma
NCT00498836
A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Hematologic Malignancies
NCT00405743
Clinical Study of Previously Untreated Patients With Malignant Melanoma
NCT00232726
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 3 |
| Phase 3 | 1 |
Therapeutic Areas
How the Clavis Pharma early-phase archive is shaped
5 indexed studies, none listed as recruiting (0% open); 5 completed (100%).
Phase mix: 1 late (III/IV) vs 4 early (I/II) (early-phase heavy).
Top condition: Acute Myeloid Leukemia (AML) (1 trial), 0 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Clavis Pharma: archived-pipeline peers nationwide
Peers matched on 5 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Clavis Pharma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 5 archived trials
- 4YouandMe · 5 trials · 0% recruiting
- Abbott Rapid Dx · 5 trials · 0% recruiting
- Access Business Group · 5 trials · 0% recruiting
- Acera Surgical · 5 trials · 20% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Clavis Pharma page
5 registered trials is a research-attention snapshot, not an endorsement of Clavis Pharma or any single study.
- None of Clavis Pharma's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Acute Myeloid Leukemia (AML) is the condition Clavis Pharma studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Acute Myeloid Leukemia (AML) trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Clavis Pharma pipeline card: 5 registered trials from official public datasets.Report a data error.